QTREX Quantum Ltd. (QTEX) 12-Month Stock Forecast & Price Target Cone

$1.22 -7.58% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.20

QTREX Quantum Ltd. (QTEX) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $73.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on QTEX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is QTEX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, QTREX Quantum Ltd. (NASDAQ: QTEX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.22 (-7.58% 1D, market cap $73.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, QTEX ranks #816 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does QTEX compare to LNSR and MBOT in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), QTEX carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 0.7%, and ROIC of -35.0%. By comparison, LNSR (LENSAR Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $73.3M) and MBOT (Microbot Medical Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -15.8%, cap $75.2M). Among the 5-stock peer group, QTEX leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for QTEX?
▼

Per QTEX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001837493), QTREX Quantum Ltd. generated $289.0K in revenue, -$13.2M in net income, and -$10.0M in free cash flow against $5.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.20 (-1.55%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510031
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (7)Whales (7)SEC (8)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.3% Base Target
$4 Bull$1 Base$1 Bear
📬 FREE QTEX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for QTEX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY QTEX SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0.2% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
39
Grade E$1.87-19.8% Next Q
Q2 (-2Q)
36
Grade E$1.50-7.3% Next Q
Q3 (-1Q)
34
Grade E$1.39-12.2% Next Q
Current
31
Grade E$1.22-9.4% Hist 90D α
Trajectory: E (39) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a QTEX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While QTEX currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.09) and Max Pain ($1.28) forces dealer call-delta covering toward $4.04.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $QTEX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “QTEX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your QTEX Position Size: $10,000

Shares at $1.22: 8196.7 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $0.83
$6,803
$-3,197 (-32.0%)
12M Consensus BaseTarget $1.07
$8,770
$-1,230 (-12.3%)
12M Bull Case BreakoutTarget $4.04
$33,115
+$23,115 (+231.1%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$174%A
Goldman SachsSector Coverage LeadUNDERPERFORM$469%B
JP MorganUS Large-Cap ResearchSELL$158%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring QTEX)

  • ✓Walkthrough of QTEX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
QTEX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +177.27%📐 HORIZONTAL RANGE
2026-10-30O $1.25H $1.25L $1.18C $1.22VOL 2.70M
RES: $2.17SUP: $0.44SMA50: $1.09SMA200: $0.97
$4.10$3.06$2.03$0.99$-0.04RES $2.17SUP $0.44$1.222026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

QTEX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on QTEX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for QTEX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for QTEX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QTEX)

Health Care Rank #816 of 1016 ⚔️ LNSR vs QTEX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (QTEX vs. LNSR, MBOT, DAVI, SKIN)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, QTREX Quantum Ltd. (QTEX) ranks #816 by composite RQD confidence (31/100, grade E) and #699 by equity capitalization ($73.9M). Within this direct 5-issuer industry benchmark cohort, QTEX leads on earnings valuation at N/A trailing P/E, while MBOT leads on capital efficiency and profitability with -15.8% ROIC and — gross margin. DAVI currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with QTEX at 31/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
QTEX ACTIVE
QTREX Quantum Ltd.
E 31/100 — 0.7% -35.0% -7.58% $73.9M Benchmark Subject
LNSR
LENSAR Inc.
E 24/100 — 39.4% -35.0% -2.18% $73.3M /lnsr-vs-qtex →
MBOT
Microbot Medical Inc.
D- 41/100 — — -15.8% -2.68% $75.2M /mbot-vs-qtex →
DAVI
Davion Healthcare Plc
D 47/100 — — — -37.55% $67.3M /davi-vs-qtex →
SKIN
SkinHealth Systems Inc. (Class A)
D- 36/100 — 65.3% -26.9% -2.07% $66.0M /skin-vs-qtex →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001837493

In its most recent audited fiscal period (FY2025, filed 2025-12-31), QTREX Quantum Ltd. (QTEX) reported GAAP revenue of $289.0K (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$13.2M, operating cash flow of -$9.9M, and free cash flow of -$10.0M (-4.5% YoY). On the balance sheet, QTEX closed FY2025 with $5.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $289.0K -$13.2M -$9.9M -$10.0M $5.3M —
FY2024 (FY) 2024-12-31 $0 -$11.1M -$9.4M -$9.5M $8.1M —
FY2023 (FY) 2023-12-31 $0 -$11.3M -$9.7M -$9.7M — —

3. QTEX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is QTEX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, QTREX Quantum Ltd. (NASDAQ: QTEX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.22 (-7.58% 1D, market cap $73.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, QTEX ranks #816 in composite RQD confidence.

How does QTEX compare to LNSR and MBOT in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), QTEX carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 0.7%, and ROIC of -35.0%. By comparison, LNSR (LENSAR Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $73.3M) and MBOT (Microbot Medical Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -15.8%, cap $75.2M). Among the 5-stock peer group, QTEX leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for QTEX?

Per QTEX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001837493), QTREX Quantum Ltd. generated $289.0K in revenue, -$13.2M in net income, and -$10.0M in free cash flow against $5.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is QTEX trading relative to its 50-day, 200-day, and 52-week technical levels?

QTEX last traded at $1.22 (-7.58% on volume of 2,795,072 shares), positioning the stock +11.93% above its 50-day simple moving average ($1.09) and +25.77% above its 200-day simple moving average ($0.97). Across its 52-week range of $0.28 to $3.85, QTEX sits at the 26.3% percentile with a 14-day RSI of 46.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.07 to $1.37).

QTEX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is QTEX's 12-month stock price target?

QTREX Quantum Ltd. (QTEX) carries a 12-month consensus base price target of $1.07 (-12.3% from $1.22), with a bull-case target of $4.04 and a bear-case floor of $0.83.

Is QTEX stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates QTEX E (Strong Sell — SELL) with an RQD Confidence score of 31/100.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%